Identification

Name
Oxycodone
Accession Number
DB00497  (APRD00387)
Type
Small Molecule
Groups
Approved, Illicit, Investigational
Description

Oxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.

Structure
Thumb
Synonyms
  • (-)-14-Hydroxydihydrocodeinone
  • 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • 4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydro-14-hydroxycodeinone
  • Dihydrohydroxycodeinone
  • Dihydroxycodeinone
  • Oxicodona
  • Oxycodone
  • Oxycodonum
External IDs
IDS-NO-002 / N02AA05 / NSC-19043 / PF-00345439 / PTI-821
Product Ingredients
IngredientUNIICASInChI Key
Oxycodone hydrochlorideC1ENJ2TE6C124-90-3MUZQPDBAOYKNLO-RKXJKUSZSA-N
Oxycodone terephthalateM04XWV43UF124133-68-2BTEYIHUKHHAVAN-KDKWOIFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Oxycodone CRTablet, extended release20 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release80 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release10 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release40 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release5 mgOralActavis Pharma Company2012-11-26Not applicableCanada
OxaydoTablet5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralEgalet Ltd2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralEgalet Ltd2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-01Not applicableUs
OxectaTablet7.5 mg/1OralPfizer Laboratories Div Pfizer Inc.2011-06-17Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxycodone CRTablet, extended release40 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release5.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release80.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release30 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release60 mgOralApotex Corporation2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release20.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release10.0 mgOralApotex Corporation2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release15 mgOralApotex Corporation2012-11-27Not applicableCanada
Oxycodone HClTablet30 mg/1OralDirectrx2016-02-22Not applicableUs
Oxycodone HCLTablet15 mg/1OralDirectrx2016-02-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-oxycodone/acetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralApotex Corporation2009-04-15Not applicableCanada
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2003-03-062018-03-15Us
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
EndocetOxycodone hydrochloride (7.5 mg/1) + Acetaminophen (500 mg/1)TabletOralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-022017-02-03Us
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2000-05-26Not applicableUs
EndocetOxycodone hydrochloride (10 mg/1) + Acetaminophen (325 mg/1)TabletOralStat Rx USA2003-03-062018-02-08Us
EndocetOxycodone hydrochloride (5 mg) + Acetaminophen (325 mg)TabletOralBristol Myers Squibb1995-12-31Not applicableCanada
EndocetOxycodone hydrochloride (5 mg/1) + Acetaminophen (325 mg/1)TabletOralLake Erie Medical Dba Quality Care Produts Llc2000-05-262018-03-15Us
EndocetOxycodone hydrochloride (2.5 mg/1) + Acetaminophen (325 mg/1)TabletOralPar Pharmaceutical2003-03-06Not applicableUs
International/Other Brands
Oxanest / OxyIR
Categories
UNII
CD35PMG570
CAS number
76-42-6
Weight
Average: 315.3636
Monoisotopic: 315.147058165
Chemical Formula
C18H21NO4
InChI Key
BRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O

Pharmacology

Indication

For the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.

Structured Indications
Pharmacodynamics

Oxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.

Mechanism of action

Oxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AKappa-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor 2b
agonist
Human
Ualpha1-acid glycoprotein
binder
Human
Absorption

Well absorbed with an oral bioavailability of 60% to 87%

Volume of distribution
  • 2.6 L/kg
Protein binding

45%

Metabolism

Hepatic

Route of elimination

Oxycodone and its metabolites are excreted primarily via the kidney.

Half life

4.5 hours

Clearance
  • 0.8 L/min [adults]
Toxicity

Symptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxycodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Oxycodone.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Oxycodone.Experimental
AbirateroneThe serum concentration of Oxycodone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Oxycodone.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Agomelatine.Approved, Investigational
AlaproclateOxycodone may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Oxycodone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Oxycodone.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxycodone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alvimopan.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Oxycodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Oxycodone.Approved, Illicit, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxycodone.Approved
ApalutamideThe serum concentration of Oxycodone can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Oxycodone.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Oxycodone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Asenapine.Approved
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Oxycodone.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Oxycodone.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Oxycodone.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxycodone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxycodone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azaperone.Investigational, Vet Approved
AzelastineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxycodone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Oxycodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxycodone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzocaine.Approved, Investigational
BenzphetamineBenzphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Oxycodone can be decreased when combined with Betaxolol.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Oxycodone.Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Oxycodone.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Oxycodone.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Oxycodone.Approved, Investigational
BosentanThe serum concentration of Oxycodone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Oxycodone.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromisoval.Experimental
BromotheophyllineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromotheophylline.Approved
BromperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bupivacaine.Approved, Investigational
BuprenorphineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Oxycodone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Oxycodone.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Oxycodone.Approved, Investigational, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Oxycodone is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Oxycodone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Oxycodone.Withdrawn
CelecoxibThe metabolism of Oxycodone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Oxycodone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxycodone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Oxycodone can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxycodone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Oxycodone.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Oxycodone.Experimental
ChlorpromazineThe metabolism of Oxycodone can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Oxycodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Oxycodone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Oxycodone can be decreased when combined with Citalopram.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Oxycodone.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clidinium.Approved
ClobazamThe metabolism of Oxycodone can be decreased when combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Oxycodone can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Oxycodone.Approved, Vet Approved
ClozapineThe metabolism of Oxycodone can be decreased when combined with Clozapine.Approved
CobicistatThe risk or severity of adverse effects can be increased when Cobicistat is combined with Oxycodone.Approved
CocaineThe metabolism of Oxycodone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxycodone.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Oxycodone.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Oxycodone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxycodone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Oxycodone.Investigational
DarifenacinThe metabolism of Oxycodone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Oxycodone.Approved
DasatinibThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Oxycodone.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane.Approved
DesipramineThe metabolism of Oxycodone can be decreased when combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxycodone.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.Approved
DesvenlafaxineOxycodone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxycodone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxycodone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Oxycodone.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Oxycodone can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Oxycodone can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxepin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Oxycodone.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxycodone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit
DronedaroneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Oxycodone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Oxycodone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efonidipine.Approved, Investigational
EliglustatThe metabolism of Oxycodone can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eltanolone.Investigational
EluxadolineOxycodone may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Oxycodone.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.Approved
EpitizideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Epitizide.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplerenone.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Oxycodone.Approved, Investigational, Vet Approved
EscitalopramOxycodone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxycodone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Oxycodone.Experimental
EthanolOxycodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxycodone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etomidate.Approved
EtoperidoneOxycodone may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Oxycodone.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fexofenadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Oxycodone.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Oxycodone.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Oxycodone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxycodone.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Oxycodone.Approved
FosaprepitantThe serum concentration of Oxycodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxycodone can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Oxycodone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin Enacarbil.Approved, Investigational
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Oxycodone.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxycodone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Oxycodone.Experimental
GepironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxycodone.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Oxycodone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Oxycodone.Experimental
HeroinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Oxycodone.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Oxycodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxycodone.Approved
IbopamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ibopamine.Experimental
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Oxycodone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Oxycodone.Approved
ImipramineThe metabolism of Oxycodone can be decreased when combined with Imipramine.Approved
IndalpineOxycodone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Oxycodone.Approved
IndiplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Oxycodone.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Oxycodone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Oxycodone.Withdrawn
IsavuconazoleThe serum concentration of Oxycodone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Oxycodone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxycodone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Oxycodone can be decreased when combined with Isoniazid.Approved, Investigational
IsosorbideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isosorbide.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Oxycodone.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Oxycodone.Approved, Investigational
IvacaftorThe serum concentration of Oxycodone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Oxycodone.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Oxycodone.Approved, Nutraceutical, Withdrawn
LamotrigineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranOxycodone may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Oxycodone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Oxycodone can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxycodone.Approved
LorcaserinThe metabolism of Oxycodone can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Oxycodone can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Oxycodone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.Approved
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Oxycodone.Approved
LumacaftorThe metabolism of Oxycodone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Oxycodone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Oxycodone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Oxycodone can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Oxycodone.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Oxycodone.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Oxycodone.Investigational
MephentermineMephentermine may increase the analgesic activities of Oxycodone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved
MethadoneThe metabolism of Oxycodone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxycodone.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxycodone.Approved
MethotrimeprazineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Oxycodone.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Oxycodone.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Oxycodone.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Oxycodone.Approved
MeticraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxycodone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.Approved
MetoprololThe metabolism of Oxycodone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineOxycodone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Oxycodone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Oxycodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranOxycodone may increase the serotonergic activities of Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Oxycodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
MirabegronThe metabolism of Oxycodone can be decreased when combined with Mirabegron.Approved
MirtazapineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Oxycodone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Oxycodone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxycodone.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Oxycodone.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
NalbuphineNalbuphine may decrease the analgesic activities of Oxycodone.Approved
NaltrexoneThe therapeutic efficacy of Oxycodone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Oxycodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone.Approved
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Oxycodone.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Nevirapine is combined with Oxycodone.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Oxycodone.Withdrawn
NicardipineThe metabolism of Oxycodone can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Oxycodone.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Oxycodone.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Oxycodone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Opium.Approved, Illicit
OrphenadrineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Oxycodone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Oxycodone.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxetacaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Oxycodone.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxybuprocaine.Approved, Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxycodone.Approved
PalbociclibThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxycodone.Approved
PanobinostatThe serum concentration of Oxycodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeOxycodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Oxycodone.Approved
ParoxetineThe metabolism of Oxycodone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Penfluridol.Experimental
PentazocinePentazocine may decrease the analgesic activities of Oxycodone.Approved, Vet Approved
PentobarbitalThe metabolism of Oxycodone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxycodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
PerazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxycodone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxycodone.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxycodone.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Oxycodone.Withdrawn
PhenobarbitalThe metabolism of Oxycodone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Oxycodone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Oxycodone.Approved, Illicit
PhenytoinThe metabolism of Oxycodone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxycodone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piretanide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piritramide.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Oxycodone.Approved
PitolisantThe serum concentration of Oxycodone can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Oxycodone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Oxycodone.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium.Approved, Investigational
Potassium CitrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PramipexoleOxycodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Oxycodone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Oxycodone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Oxycodone.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxycodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxycodone.Approved
PromazineThe metabolism of Oxycodone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Oxycodone.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxycodone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Oxycodone.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Oxycodone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxycodone.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Oxycodone is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Oxycodone.Approved
QuazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinethazone.Approved
QuinidineThe metabolism of Oxycodone can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Oxycodone can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon.Approved, Investigational
RamosetronOxycodone may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe risk or severity of adverse effects can be increased when Ranolazine is combined with Oxycodone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxycodone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxycodone.Approved, Investigational
RifabutinThe metabolism of Oxycodone can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Oxycodone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Oxycodone can be increased when combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Oxycodone can be decreased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Oxycodone.Investigational
RitonavirThe metabolism of Oxycodone can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Oxycodone can be decreased when combined with Rolapitant.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Romifidine.Vet Approved
RopiniroleOxycodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ropivacaine.Approved
RotigotineOxycodone may increase the sedative activities of Rotigotine.Approved
RucaparibThe risk or severity of adverse effects can be increased when Rucaparib is combined with Oxycodone.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxycodone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Oxycodone.Withdrawn
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.Approved, Investigational
SarilumabThe therapeutic efficacy of Oxycodone can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Oxycodone.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Oxycodone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Oxycodone.Approved, Investigational
SiltuximabThe serum concentration of Oxycodone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Oxycodone.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxycodone.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Oxycodone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Oxycodone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Oxycodone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Oxycodone.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sultopride.Experimental
SuvorexantOxycodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tasimelteon.Approved, Investigational
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Oxycodone.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Oxycodone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxycodone.Approved, Investigational
TerbinafineThe metabolism of Oxycodone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrodotoxin.Investigational
ThalidomideOxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Oxycodone.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxycodone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Oxycodone.Approved
ThioridazineThe metabolism of Oxycodone can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiapride.Approved, Investigational
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Oxycodone.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxycodone.Approved
TipranavirThe metabolism of Oxycodone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Oxycodone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxycodone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxycodone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxycodone.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Oxycodone.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxycodone.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxycodone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxycodone.Approved
UlaritideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxycodone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Oxycodone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxycodone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vinyl ether.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Oxycodone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziconotide.Approved
ZimelidineOxycodone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zolazepam.Vet Approved
ZolpidemOxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, "Preparation of oxycodone from codeine." U.S. Patent US6008355, issued March, 1990.

US6008355
General References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
External Links
Human Metabolome Database
HMDB0014640
KEGG Drug
D05312
KEGG Compound
C08018
PubChem Compound
5284603
PubChem Substance
46508908
ChemSpider
4447649
BindingDB
50370595
ChEBI
7852
ChEMBL
CHEMBL656
Therapeutic Targets Database
DAP000283
PharmGKB
PA450741
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxycodone
ATC Codes
N02AA55 — Oxycodone, combinationsN02AA05 — Oxycodone
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (689 KB)
MSDS
Download (50.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentLocally Advanced Head and Neck Cancer1
0RecruitingTreatmentUrologic Diseases1
1CompletedNot AvailableHealthy Volunteers15
1CompletedNot AvailableOpioid Analgesia1
1CompletedNot AvailableOsteoarthritis Thumbs1
1CompletedNot AvailablePain1
1CompletedBasic ScienceAnalgesia / Narcotic Abuse / Opioid-Related Disorders / Pain, Acute / Pain, Chronic1
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceManagement of Moderate to Severe Pain1
1CompletedBasic ScienceOpioid Users1
1CompletedBasic SciencePain2
1CompletedOtherOpioid Abuse Nondependent1
1CompletedOtherPain, Chronic3
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentPain2
1RecruitingOtherPain, Chronic1
1RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentHealthy Volunteers1
1, 2CompletedTreatmentPain, Fracture, Sprain1
2CompletedBasic ScienceOpioid-Related Disorders / Substance-Related Disorders1
2CompletedSupportive CarePain1
2CompletedTreatmentCancers / Occasional Constipation / Pain1
2CompletedTreatmentCancers / Pain1
2CompletedTreatmentDental Pain1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentOpioid Abuse1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPostoperative pain3
2Not Yet RecruitingBasic ScienceOpioid Abuse / Opioid-use Disorder1
2Not Yet RecruitingSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture / Trigger Digit1
2Not Yet RecruitingTreatmentOpioid-Related Disorders / Opioids Use / Rib Fractures1
2Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentOpioid-use Disorder1
2RecruitingTreatmentPain Management1
2RecruitingTreatmentTonsillectomy1
2TerminatedTreatmentOsteoarthritis (OA)1
2TerminatedTreatmentToothache1
2, 3CompletedTreatmentMalignant Pain / Non-malignant Pain1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Active Not RecruitingTreatmentGynecologic Cancers / Malignant Neoplasms of Female Genital Organs1
3CompletedNot AvailableSubjects With Moderate to Severe, Chronic Nonmalignant Pain1
3CompletedNot AvailableWithdrawal Symptoms1
3CompletedBasic ScienceLow Back Pain (LBP)1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedSupportive CareChronic Noncancer Pain1
3CompletedSupportive CarePain1
3CompletedTreatmentAnalgesia / Low Back Pain (LBP) / Pain, Chronic1
3CompletedTreatmentArthralgia / Bunions / Hallux Valgus / Pain1
3CompletedTreatmentArthritis / Joint Diseases / Osteoarthritis (OA)1
3CompletedTreatmentBack Pain1
3CompletedTreatmentBack Pain / Back Pain With Radiation / Low Back Pain (LBP) / Pain1
3CompletedTreatmentCancers1
3CompletedTreatmentCancers / Pain1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Lower Back Pain / Osteoarthritis, Hip / Pain1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Pain1
3CompletedTreatmentLow Back Pain (LBP)2
3CompletedTreatmentModerate to Severe Postoperative Pain1
3CompletedTreatmentOpioids Use / Pain, Chronic1
3CompletedTreatmentOther Acute Postoperative Pain1
3CompletedTreatmentPain6
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentPostoperative pain5
3CompletedTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedTreatmentPruritus1
3CompletedTreatmentRenal Stones1
3Not Yet RecruitingTreatmentAbortion in First Trimester1
3Not Yet RecruitingTreatmentPain, Chronic1
3RecruitingSupportive CareBreast - Female1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentBack Pain / Cervical Pain1
3RecruitingTreatmentJoint Diseases1
3TerminatedTreatmentArthroplasty1
3TerminatedTreatmentOsteoarthritis (OA)1
3TerminatedTreatmentSevere Caner Pain1
3Unknown StatusSupportive CareCancers / Pain1
3Unknown StatusTreatmentBreakthrough Cancer Pain1
4Active Not RecruitingTreatmentCritical Illness1
4Active Not RecruitingTreatmentMAB / Pain1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailablePain1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceHealthy, no Evidence of Disease1
4CompletedBasic ScienceSubstance-Related Disorders1
4CompletedDiagnosticPain1
4CompletedSupportive CareCancers1
4CompletedSupportive CareEffects of 2 Mu-opiates on Gastrointestinal Transit1
4CompletedSupportive CarePain, Chronic1
4CompletedSupportive CarePain / Unspecified Adult Solid Tumor, Protocol Specific1
4CompletedSupportive CareSpinal Disorders / Spinal Disorders Related Pain1
4CompletedTreatmentArthroplasty, Replacement, Hip1
4CompletedTreatmentBack Pain / Low Back Pain (LBP) / Pain, Neuropathic1
4CompletedTreatmentBack Pain / Osteoarthritis (OA)1
4CompletedTreatmentBenign muscle neoplasm / Hysterectomy / Opioids / Postoperative pain1
4CompletedTreatmentCancers2
4CompletedTreatmentCancers / Pain, Cancer1
4CompletedTreatmentChronic Low Back Pain (CLBP) / Depression / Feeling Anxious / Intervertebral Disc Degeneration1
4CompletedTreatmentDisorder of Knee1
4CompletedTreatmentFlank Pain / Urinary Bladder, Overactive1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentImpaired Renal Function / Myocardial Infarction (MI) / Postoperative pain1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNausea1
4CompletedTreatmentOccasional Constipation1
4CompletedTreatmentOocyte Retrieval / Postoperative pain1
4CompletedTreatmentOpioid Related Disorders / Postoperative pain1
4CompletedTreatmentLumbar epidural anesthesia / Oral Oxycodone With/Without Naloxone / Postoperative Pain Management / Radical Cystectomy / Return of the Bowel Function1
4CompletedTreatmentOsteoarthritis (OA) / Pain, Chronic1
4CompletedTreatmentPain2
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPain, Cancer1
4CompletedTreatmentPost Operative Pain2
4CompletedTreatmentPostcraniotomy Pain1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentUnilateral Knee Arthroplasty1
4Not Yet RecruitingTreatmentDistal Radius Fractures / Metacarpal Fractures / Pain Management1
4Not Yet RecruitingTreatmentInguinal Hernias / Postoperative pain1
4Not Yet RecruitingTreatmentOxycodone / Pharmacogenomics / Pharmacokinetics1
4Not Yet RecruitingTreatmentPain2
4Not Yet RecruitingTreatmentPostoperative pain2
4RecruitingBasic ScienceChronic Kidney Disease (CKD)1
4RecruitingOtherPediatric Surgical Patient1
4RecruitingSupportive CareScoliosis / Spondylolisthesis1
4RecruitingTreatmentAnalgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use / Opioids Use / Pain Uterus / Pain, Acute / Postoperative pain / Visceral Pain1
4RecruitingTreatmentBody Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentDiseases of Mitral Valve / Postoperative pain1
4RecruitingTreatmentDrug Abuse / Narcotic Abuse / Opiate Addiction / Opioid-Related Disorders1
4RecruitingTreatmentHip Arthroscopy1
4RecruitingTreatmentLabour Pain1
4RecruitingTreatmentOccasional Constipation / Postoperative pain1
4RecruitingTreatmentOral Sedation and Cervical Dilator Pain1
4RecruitingTreatmentPain3
4RecruitingTreatmentPain Management1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentSleep Apnea Syndrome1
4SuspendedTreatmentPain, Chronic1
4TerminatedNot AvailablePeripheral Neuropathy1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4TerminatedTreatmentDisseminated Sclerosis / Pain, Chronic / Pain, Neuropathic1
4TerminatedTreatmentPain, Chronic1
4Unknown StatusNot AvailableOpioid Induced Constipation (OIC) / Postoperative pain1
4Unknown StatusTreatmentAcute Low Back Pain1
4Unknown StatusTreatmentElective Laproscopic Bilateral Inguinal Hernia / Elective Laproscopic Cholecystectomy1
4Unknown StatusTreatmentLow Back Pain (LBP)1
4Unknown StatusTreatmentPost Operative Pain1
4WithdrawnTreatmentPain, Chronic1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Fibrosis, Liver1
Not AvailableActive Not RecruitingSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain / Vesicular Stomatitis1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedNot AvailableChronic Severe Pain1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableSevere Pain1
Not AvailableCompletedNot AvailableSubstance Abuse Detection1
Not AvailableCompletedBasic ScienceNarcotic Abuse1
Not AvailableCompletedPreventionCoughing Responses at Tracheal Extubation1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentElbow Fractures1
Not AvailableCompletedTreatmentHip Fracture Surgery / Post Operative Pain Control1
Not AvailableCompletedTreatmentLabour Pain1
Not AvailableNot Yet RecruitingNot AvailableOxycontin1
Not AvailableNot Yet RecruitingSupportive CareNutrition Disorders / Quality of Life1
Not AvailableNot Yet RecruitingTreatmentHerpes Zoster / Post-Herpetic Neuralgia (PHN)1
Not AvailableNot Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingTreatmentChronic Pain, Postoperative / Postoperative pain1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableSuspendedTreatmentLaceration / Pain1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentAnaesthesia therapy1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableWithdrawnSupportive CareLow Back Pain (LBP)1

Pharmacoeconomics

Manufacturers
  • Mallinckrodt inc
  • Purdue pharma lp
  • Roxane laboratories inc
  • Actavis totowa llc
  • Avanthi inc
  • Corepharma llc
  • Kv pharmaceutical co
  • Sun pharmaceutical industries inc
  • Tyco healthcare mallinckrodt
  • Vintage pharmaceuticals inc
  • Xanodyne pharmaceuticals inc
  • Endo Pharmaceuticals
Packagers
  • 4uOrtho LLC
  • Actavis Group
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Athlon Pharmaceuticals Inc.
  • Atley Pharmaceuticals
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Chattem Chemicals Inc.
  • Cody Laboratories Inc.
  • Core Pharmaceuticals
  • Corepharma LLC
  • D.M. Graham Laboratories Inc.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • DSM Corp.
  • Endo Pharmaceuticals Inc.
  • Endogen
  • Ethex Corp.
  • Forest Pharmaceuticals
  • Glenmark Generics Ltd.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Ivax Pharmaceuticals
  • Janssen-Ortho Inc.
  • KV Pharmaceutical Co.
  • KVK-Tech Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Lehigh Valley Technologies Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Metrics Inc.
  • Midlothian Labs
  • Mikart Inc.
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ortho-McNeil-Janssen Pharmaceuticals Inc.
  • P F Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Purdue Pharma LP
  • Qualitest
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Rhodes Pharmaceutical LP
  • Roxane Labs
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Superior Pharmeceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Victory Pharma
  • Vindex Pharmaceuticals Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • WraSer Pharmaceuticals
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral5 mg
Tablet, extended releaseOral10.0 mg
Tablet, extended releaseOral20.0 mg
Tablet, extended releaseOral40 mg
Tablet, extended releaseOral5.0 mg
Tablet, extended releaseOral80.0 mg
TabletOral7.5 mg/1
Tablet, multilayer, extended releaseOral20 mg
Capsule, gelatin coatedOral
CapsuleOral5 mg/1
SolutionOral100 mg/5mL
SolutionOral20 mg/mL
SolutionOral5 mg/5mL
Solution, concentrateOral20 mg/mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
CapsuleOral
SolutionOral
Tablet, film coatedOral
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral80 mg/1
TabletOral80 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral80 mg
TabletOral
Tablet, coatedOral15 mg/1
Tablet, coatedOral30 mg/1
Tablet, coatedOral5 mg/1
TabletOral20 mg
SuppositoryRectal10 mg
TabletOral10 mg
SuppositoryRectal20 mg
TabletOral5 mg
Tablet, extended releaseOral
Capsule, extended releaseOral
Tablet, coatedOral
Capsule, extended releaseOral13.5 mg/1
Capsule, extended releaseOral18 mg/1
Capsule, extended releaseOral27 mg/1
Capsule, extended releaseOral36 mg/1
Capsule, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Oxycodone hcl powder53.64USD g
Roxicodone 5 mg/5ml Solution 500ml Bottle53.0USD bottle
Roxicodone 20 mg/ml Concentrate 30ml Bottle46.99USD bottle
OxyCODONE HCl 20 mg/ml Concentrate 30ml Bottle33.99USD bottle
Oxycontin 60 mg tablet17.08USD tablet
OxyCONTIN 80 mg 12 Hour tablet14.36USD tablet
Oxycontin 20 mg tablet11.87USD tablet
Oxycontin 80 mg tablet11.53USD tablet
OxyCONTIN 60 mg 12 Hour tablet10.57USD tablet
Oxycontin 40 mg tablet9.45USD tablet
OxyCODONE HCl 80 mg 12 Hour tablet8.33USD tablet
OxyCONTIN 40 mg 12 Hour tablet7.68USD tablet
Oxycontin 10 mg tablet6.89USD tablet
Oxycontin 30 mg tablet6.59USD tablet
OxyCONTIN 30 mg 12 Hour tablet5.8USD tablet
Roxicodone 30 mg tablet5.19USD tablet
Oxycontin 80 mg Sustained-Release Tablet4.69USD tablet
OxyCODONE HCl 40 mg 12 Hour tablet4.38USD tablet
OxyCONTIN 20 mg 12 Hour tablet4.27USD tablet
Oxycontin 60 mg Sustained-Release Tablet3.55USD tablet
Oxycontin 15 mg tablet3.22USD tablet
Supeudol 20 mg Suppository2.95USD suppository
Roxicodone 15 mg tablet2.83USD tablet
Oxycodone hcl 10 mg tablet2.82USD tablet
Endocet 10-650 mg tablet2.7USD tablet
Endocet 7.5-325 mg tablet2.54USD tablet
Oxycontin 40 mg Sustained-Release Tablet2.54USD tablet
OxyCONTIN 10 mg 12 Hour tablet2.53USD tablet
Supeudol 10 mg Suppository2.33USD suppository
Roxicodone intensol 20 mg/ml2.3USD ml
Endocet 7.5-500 mg tablet2.22USD tablet
Oxycodone-apap 2.5-325 mg tablet2.05USD tablet
Percodan 4.5-0.38-325 mg tablet1.98USD tablet
Oxycontin 30 mg Sustained-Release Tablet1.96USD tablet
Endocet 10-325 mg tablet1.87USD tablet
Endocet 5-325 tablet1.82USD tablet
Percodan tablet1.62USD tablet
Oxycontin 20 mg Sustained-Release Tablet1.46USD tablet
Dazidox 20 mg tablet1.44USD tablet
Oxycodone hcl 30 mg tablet1.41USD tablet
Oxycontin 15 mg Sustained-Release Tablet1.19USD tablet
Endodan 4.83-325 mg tablet1.18USD tablet
Oxycodone hcl 20 mg tablet1.1USD tablet
Oxycontin 10 mg Sustained-Release Tablet0.98USD tablet
Oxycodone hcl 15 mg tablet0.9USD tablet
Oxycodone hcl 5 mg tablet0.81USD tablet
Dazidox 10 mg tablet0.75USD tablet
Oxy-Ir 20 mg Tablet0.74USD tablet
OxyCODONE HCl 5 mg capsule0.71USD capsule
Oxycontin 5 mg Sustained-Release Tablet0.7USD tablet
Endocet 5-325 mg tablet0.6USD tablet
Roxicodone 5 mg tablet0.56USD tablet
Oxyir 5 mg capsule0.52USD capsule
Oxy-Ir 10 mg Tablet0.43USD tablet
Pms-Oxycodone 20 mg Tablet0.42USD tablet
Supeudol 20 mg Tablet0.42USD tablet
Oxycodone 5 mg tablet0.36USD tablet
Pms-Oxycodone 10 mg Tablet0.24USD tablet
Supeudol 10 mg Tablet0.24USD tablet
Pms-Oxycodone 5 mg Tablet0.14USD tablet
Supeudol 5 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5508042No1993-04-162013-04-16Us
CA2098738No1999-08-172012-11-25Canada
US9205082No2002-05-102022-05-10Us
US6488962No2000-06-202020-06-20Us
US8309060No2003-11-202023-11-20Us
US8808741No2007-08-242027-08-24Us
US9073933No2005-03-302025-03-30Us
US9060976No2002-08-062022-08-06Us
US6488963No1997-06-242017-06-24Us
US7674800No2005-03-302025-03-30Us
US7683072No2005-03-302025-03-30Us
US8337888No2002-08-062022-08-06Us
US7776314No2005-04-192025-04-19Us
US8894988No2007-08-242027-08-24Us
US7674799No2005-03-302025-03-30Us
US8114383No2004-10-102024-10-10Us
US8894987No2010-03-292030-03-29Us
US8685443No2005-07-032025-07-03Us
US7815934No2007-12-122027-12-12Us
US9168252No2002-05-102022-05-10Us
US9161937No2002-05-102022-05-10Us
US8969369No2002-05-102022-05-10Us
US9084729No2002-05-102022-05-10Us
US9283216No2002-05-102022-05-10Us
US9056051No2002-05-102022-05-10Us
US8846090No2003-04-042023-04-04Us
US6277384No1998-12-222018-12-22Us
US8822487No1998-12-222018-12-22Us
US8673355No1998-12-222018-12-22Us
US6696066No1998-12-222018-12-22Us
US8846091No2003-04-042023-04-04Us
US8372432No2009-03-112029-03-11Us
US8668929No2009-03-112029-03-11Us
US8377453No2009-11-192029-11-19Us
US7976870No2007-06-012027-06-01Us
US8741885No2012-05-162032-05-16Us
US8992975No2012-05-162032-05-16Us
US8597681No2010-12-212030-12-21Us
US8980319No2010-12-212030-12-21Us
US8394408No2009-03-112029-03-11Us
US9050335No2012-05-162032-05-16Us
US8658631No2012-05-162032-05-16Us
US7510726No2003-11-262023-11-26Us
US8409616No2003-11-262023-11-26Us
US7201920No2005-03-162025-03-16Us
US8637540No2003-11-262023-11-26Us
US7981439No2003-11-262023-11-26Us
US7955619No2008-08-122028-08-12Us
US9492389No2007-08-242027-08-24Us
US9522919No2005-03-302025-03-30Us
US9492392No2007-08-242027-08-24Us
US9492391No2007-08-242027-08-24Us
US9492393No2007-08-242027-08-24Us
US9345701No2002-05-102022-05-10Us
US9511066No2002-05-102022-05-10Us
US9555000No2003-04-042023-04-04Us
US9474750No1998-12-222018-12-22Us
US9283221No2002-05-102022-05-10Us
US9468636No2012-05-162032-05-16Us
US9492443No2004-05-262024-05-26Us
US9044398No2003-07-072023-07-07Us
US7771707No2005-03-242025-03-24Us
US9248195No2003-07-072023-07-07Us
US8557291No2005-03-212025-03-21Us
US8449909No2005-03-242025-03-24Us
US7399488No2005-03-242025-03-24Us
US9592200No2003-07-072023-07-07Us
US9682075No2010-12-102030-12-10Us
US8758813No2005-06-102025-06-10Us
US8840928No2003-07-072023-07-07Us
US9675610No2003-06-162023-06-16Us
US9737530No2016-09-022036-09-02Us
US9763933No2007-08-242027-08-24Us
US9770416No2007-08-242027-08-24Us
US9775808No2007-08-242027-08-24Us
US9763883No2003-07-072023-07-07Us
US9907793No2003-04-042023-04-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)219 °CPhysProp
water solubility100 mg/mlNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.59 mg/mLALOGPS
logP1.04ALOGPS
logP1.03ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.04 m3·mol-1ChemAxon
Polarizability32.8 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9885
Caco-2 permeable+0.7774
P-glycoprotein substrateSubstrate0.8996
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IINon-inhibitor0.9122
Renal organic cation transporterNon-inhibitor0.5413
CYP450 2C9 substrateNon-substrate0.822
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9431
CYP450 2D6 inhibitorNon-inhibitor0.5131
CYP450 2C19 inhibitorNon-inhibitor0.882
CYP450 3A4 inhibitorNon-inhibitor0.8714
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.7337
CarcinogenicityNon-carcinogens0.9557
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.0638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9402
hERG inhibition (predictor II)Non-inhibitor0.9279
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-014i-6975000000-ecd49efa58246c903e23
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-d55749fa4d1f47ce2244
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kb-0095000000-83c78e9e15857145cc78
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ad908ecfa38c7efce138
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0390000000-88d302b8770cb7121937
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fu-0790000000-4af50b834ee854320001

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / 1,2-aminoalcohols
show 7 more
Substituents
Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:7852)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433]
  3. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007 Dec 5;132(3):289-300. Epub 2007 Apr 30. [PubMed:17467904]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
4. Kappa-type opioid receptor 2b
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
References
  1. Smith MT: Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol. 2008 Oct;21(5):596-601. doi: 10.1097/ACO.0b013e32830a4c4a. [PubMed:18784485]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:46